ECSP22076856A - Inhibidores de rip1k - Google Patents
Inhibidores de rip1kInfo
- Publication number
- ECSP22076856A ECSP22076856A ECSENADI202276856A ECDI202276856A ECSP22076856A EC SP22076856 A ECSP22076856 A EC SP22076856A EC SENADI202276856 A ECSENADI202276856 A EC SENADI202276856A EC DI202276856 A ECDI202276856 A EC DI202276856A EC SP22076856 A ECSP22076856 A EC SP22076856A
- Authority
- EC
- Ecuador
- Prior art keywords
- rip1k
- inhibitors
- kinase
- inhibitory compounds
- rip1
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 abstract 3
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
En la presente descripción se describen compuestos inhibidores de quinasa, tales como los compuestos inhibidores de la proteína quinasa 1 que interactúa con el receptor (RIP1), así como también composiciones farmacéuticas y combinaciones que comprenden tales compuestos inhibidores. Los compuestos, composiciones farmacéuticas y/o combinaciones descritos pueden usarse para tratar o prevenir una enfermedad o afección asociada a quinasas, particularmente una enfermedad o afección asociada a RIP1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063004404P | 2020-04-02 | 2020-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP22076856A true ECSP22076856A (es) | 2023-02-28 |
Family
ID=75747027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202276856A ECSP22076856A (es) | 2020-04-02 | 2022-09-30 | Inhibidores de rip1k |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11584758B2 (es) |
| EP (1) | EP4126864A1 (es) |
| JP (2) | JP2023520046A (es) |
| KR (1) | KR20220161433A (es) |
| CN (1) | CN115867548B (es) |
| AR (1) | AR121717A1 (es) |
| AU (1) | AU2021246147B2 (es) |
| BR (1) | BR112022019492A2 (es) |
| CA (1) | CA3173432A1 (es) |
| CL (1) | CL2022002695A1 (es) |
| CO (1) | CO2022014137A2 (es) |
| CR (1) | CR20220492A (es) |
| DO (1) | DOP2022000215A (es) |
| EC (1) | ECSP22076856A (es) |
| IL (1) | IL296916A (es) |
| JO (1) | JOP20220246A1 (es) |
| MX (1) | MX2022012305A (es) |
| PE (1) | PE20230560A1 (es) |
| PH (1) | PH12022552638A1 (es) |
| SA (1) | SA522440778B1 (es) |
| TW (1) | TW202204364A (es) |
| UA (1) | UA128751C2 (es) |
| WO (1) | WO2021203011A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3317269B1 (en) * | 2015-07-02 | 2022-09-21 | F. Hoffmann-La Roche AG | Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases |
| WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
| MD3788045T2 (ro) | 2018-05-03 | 2023-09-30 | Rigel Pharmaceuticals Inc | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora |
| HRP20231381T1 (hr) | 2018-05-03 | 2024-03-01 | Rigel Pharmaceuticals, Inc. | Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu |
| CA3149926A1 (en) | 2019-09-06 | 2021-03-11 | Yan Chen | Rip1 inhibitory compounds and methods for making and using the same |
| JP7493586B2 (ja) | 2019-09-06 | 2024-05-31 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法 |
| CA3169099A1 (en) * | 2020-02-28 | 2021-09-02 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase i for the treatment of disease |
| AR121717A1 (es) * | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI840311B (zh) | 2020-07-01 | 2024-04-21 | 美商雷傑製藥公司 | Rip1k抑制劑 |
| TW202334164A (zh) * | 2022-01-12 | 2023-09-01 | 美商戴納立製藥公司 | （Ｓ）－５－苄基－Ｎ－（５－甲基－４－側氧基－２，３，４，５－四氫吡啶並［３，２－ｂ］［１，４］氧氮呯－３－基）－４Ｈ－１，２，４－三唑－３－甲醯胺的晶型 |
| WO2023138317A1 (zh) * | 2022-01-21 | 2023-07-27 | 中国科学院上海药物研究所 | 具有ripk1抑制活性的化合物、其制备方法及其用途 |
| CN116640156B (zh) * | 2022-02-22 | 2025-10-24 | 上海齐鲁制药研究中心有限公司 | Ripk1抑制剂 |
| US20250197390A1 (en) * | 2022-03-16 | 2025-06-19 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fused heterocyclic compound, and preparation method therefor and medical use thereof |
| CN118108633A (zh) * | 2024-01-17 | 2024-05-31 | 浙江工业大学 | 一种l-草铵膦中间体(s)-2-(((苄氧基)羰基)氨基)丁-3-烯酸甲酯的制备方法 |
| WO2025153090A1 (zh) * | 2024-01-19 | 2025-07-24 | 无锡奕拓医药科技有限责任公司 | 一种多并环化合物、其药物组合物及其用途 |
| EP4652998A1 (en) * | 2024-05-21 | 2025-11-26 | Technische Universität München | Treatment of receptor-interacting protein kinase 1- mediated disease with eclitasertib |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2192838A4 (en) | 2007-08-15 | 2011-07-27 | Harvard College | HETEROCYCLIC NEKROPTOSIS HEMMER |
| TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
| US20160024098A1 (en) | 2013-03-15 | 2016-01-28 | President And Fellows Of Harvard College | Hybrid necroptosis inhibitors |
| CN106573006A (zh) | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
| BR112017017411A2 (pt) | 2015-02-13 | 2018-04-03 | Glaxosmithkline Ip Dev Ltd | Formas cristalinas de (s)-5-benzil-n-(5-metil-4-oxo- 2,3,4,5-tetraidrobenzo[b][1,4]oxazepin-3-il)-4h-1,2,4- triazol-3-carboxamida |
| EP3317269B1 (en) | 2015-07-02 | 2022-09-21 | F. Hoffmann-La Roche AG | Bicyclic lactams as receptor-interacting protein-1 (rip1) kinase inhibitors for treating e.g. inflammatory diseases |
| ES2885474T3 (es) | 2015-10-13 | 2021-12-13 | Inst Nat Sante Rech Med | Derivados de sibirilina para la utilización en la prevención y/o tratamiento de trastornos asociados a la necroptosis celular |
| AU2016340527B2 (en) * | 2015-10-23 | 2020-09-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| IL287136B2 (en) | 2016-02-05 | 2023-09-01 | Denali Therapeutics Inc | Receptor inhibitors - interacting with protein kinase 1 |
| WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| US20200062735A1 (en) | 2017-02-27 | 2020-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| CA3068305A1 (en) * | 2017-06-29 | 2019-01-03 | Rigel Pharmaceuticals, Inc. | Kinase inhibitors and methods for making and using |
| WO2019204537A1 (en) * | 2018-04-20 | 2019-10-24 | Genentech, Inc. | N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs) |
| HRP20231381T1 (hr) | 2018-05-03 | 2024-03-01 | Rigel Pharmaceuticals, Inc. | Spojevi inhibitori rip1 i postupci za njihovo dobivanje i upotrebu |
| MD3788045T2 (ro) * | 2018-05-03 | 2023-09-30 | Rigel Pharmaceuticals Inc | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora |
| TW202019913A (zh) | 2018-06-26 | 2020-06-01 | 中國科學院上海有機化學研究所 | 細胞壞死抑制劑及其製備方法和用途 |
| CN109134448B (zh) * | 2018-10-16 | 2020-11-27 | 中南大学湘雅医院 | 杂环化合物及其盐、制备方法、用途和药物 |
| WO2020088194A1 (zh) | 2018-11-02 | 2020-05-07 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| CN111138448B (zh) | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| AU2020285269B2 (en) | 2019-05-31 | 2022-11-17 | Medshine Discovery Inc. | Bicyclic compound as RIP-1 kinase inhibitor and application thereof |
| CA3149926A1 (en) | 2019-09-06 | 2021-03-11 | Yan Chen | Rip1 inhibitory compounds and methods for making and using the same |
| JP7493586B2 (ja) | 2019-09-06 | 2024-05-31 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｒｉｐ１阻害化合物ならびにそれを作製および使用するための方法 |
| SI4055021T1 (sl) | 2019-11-07 | 2026-02-27 | Rigel Pharmaceuticals, Inc. | Heterociklične spojine, ki inhibirajo rip1 |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| TWI840311B (zh) | 2020-07-01 | 2024-04-21 | 美商雷傑製藥公司 | Rip1k抑制劑 |
-
2021
- 2021-03-31 AR ARP210100820A patent/AR121717A1/es unknown
- 2021-04-01 TW TW110112096A patent/TW202204364A/zh unknown
- 2021-04-02 BR BR112022019492A patent/BR112022019492A2/pt unknown
- 2021-04-02 CN CN202180038481.3A patent/CN115867548B/zh active Active
- 2021-04-02 WO PCT/US2021/025598 patent/WO2021203011A1/en not_active Ceased
- 2021-04-02 KR KR1020227037796A patent/KR20220161433A/ko active Pending
- 2021-04-02 EP EP21722607.5A patent/EP4126864A1/en active Pending
- 2021-04-02 PH PH1/2022/552638A patent/PH12022552638A1/en unknown
- 2021-04-02 CA CA3173432A patent/CA3173432A1/en active Pending
- 2021-04-02 PE PE2022002161A patent/PE20230560A1/es unknown
- 2021-04-02 US US17/221,493 patent/US11584758B2/en active Active
- 2021-04-02 AU AU2021246147A patent/AU2021246147B2/en active Active
- 2021-04-02 UA UAA202203662A patent/UA128751C2/uk unknown
- 2021-04-02 IL IL296916A patent/IL296916A/en unknown
- 2021-04-02 CR CR20220492A patent/CR20220492A/es unknown
- 2021-04-02 JP JP2022559872A patent/JP2023520046A/ja active Pending
- 2021-04-02 MX MX2022012305A patent/MX2022012305A/es unknown
-
2022
- 2022-09-30 EC ECSENADI202276856A patent/ECSP22076856A/es unknown
- 2022-09-30 DO DO2022000215A patent/DOP2022000215A/es unknown
- 2022-09-30 CO CONC2022/0014137A patent/CO2022014137A2/es unknown
- 2022-09-30 CL CL2022002695A patent/CL2022002695A1/es unknown
- 2022-10-02 SA SA522440778A patent/SA522440778B1/ar unknown
- 2022-10-04 JO JOP/2022/0246A patent/JOP20220246A1/ar unknown
-
2023
- 2023-01-13 US US18/154,255 patent/US12043629B2/en active Active
-
2024
- 2024-11-08 JP JP2024196081A patent/JP2025032106A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115867548B (zh) | 2025-03-11 |
| SA522440778B1 (ar) | 2025-07-08 |
| MX2022012305A (es) | 2023-03-06 |
| PH12022552638A1 (en) | 2023-01-16 |
| TW202204364A (zh) | 2022-02-01 |
| KR20220161433A (ko) | 2022-12-06 |
| US12043629B2 (en) | 2024-07-23 |
| US11584758B2 (en) | 2023-02-21 |
| AU2021246147A1 (en) | 2022-10-20 |
| CN115867548A (zh) | 2023-03-28 |
| CR20220492A (es) | 2023-02-09 |
| CA3173432A1 (en) | 2021-10-07 |
| UA128751C2 (uk) | 2024-10-09 |
| AR121717A1 (es) | 2022-06-29 |
| BR112022019492A2 (pt) | 2022-11-16 |
| IL296916A (en) | 2022-12-01 |
| JOP20220246A1 (ar) | 2023-01-30 |
| US20230227469A1 (en) | 2023-07-20 |
| US20210317135A1 (en) | 2021-10-14 |
| WO2021203011A1 (en) | 2021-10-07 |
| JP2025032106A (ja) | 2025-03-11 |
| AU2021246147B2 (en) | 2024-01-18 |
| DOP2022000215A (es) | 2023-02-28 |
| EP4126864A1 (en) | 2023-02-08 |
| CO2022014137A2 (es) | 2023-03-07 |
| PE20230560A1 (es) | 2023-03-31 |
| JP2023520046A (ja) | 2023-05-15 |
| CL2022002695A1 (es) | 2023-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022014137A2 (es) | Inhibidores de rip1k | |
| DOP2022000051A (es) | Compuestos inhibidores de rip1 y métodos para hacer y utilizar los mismos | |
| DOP2023000169A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| DOP2022000042A (es) | Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos | |
| ECSP20077518A (es) | Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos | |
| MX2022005509A (es) | Compuestos inhibidores de rip1 heterociclicos. | |
| CO2023000051A2 (es) | Inhibidores de rip1k | |
| PY2055444A (es) | Composiciones nematicidas | |
| AR120412A1 (es) | Compuestos heterocíclicos inhibidores de rip1 | |
| CO2023012077A2 (es) | Inhibidores heterocíclicos de la cinasa rip1 |